Advanced Cell Technology announces site for Stargardt's stem cell trial Print E-mail
By Olivia D'   
Monday, 16 May 2011 18:59

Advanced Cell Technology (ACT) (OTCBB:ACTC) announced Monday that the Casey Eye Institute in Portland, Oregon, will be the site for an upcoming clincal trial testing its stem cell-based treatment for Stargardt's Macular Dystrophy (SMD), a degenerative eye disease seen in younger people.

SMD is the most common form of the degenerative disease of the retina. The disease is usually first diagnosed in children aged 10 to 20 years old, and causes progressive vision loss.

Eventually, blindness results from photoreceptor loss associated with degeneration in a layer of the retina, called the retinal pigment epithelium (RPE).

Advanced Cell's treatment has the potential to supply an unlimited amount of healthy RPE cells, as the process involves the transplant of RPE cells derived from human stem cells.

In November 2010, the company recieved FDA approval to begin its first clinical trial in the US that tests the stem cell therapy in 12 patients with advanced Stargardt's.

ACT, a biotechnology company focused on applying cellular technology in the field of regenerative medicine, hopes that the trials will illuminate the roll that RPE cells can play in the treatment of SMD, said ACT CEO, Gary Rabin.

The phase I/II of the human clinical trial is designed to test the safety and the tolerance of RPE cells following their transplant into SMD patients, and is scheduled to begin in the coming weeks.

“Proactiveinvestors is a leading news organisation and event business with offices in New York, Sydney, Toronto and London. The Company is a publisher and is not registered with the US Securities Exchange Commission or Ontario Securities Commission. Please read our full terms and conditions here

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus